EUVIMEDEUVIMED entdecken
Crossref

Design, Synthesis, and Biological Evaluation of Potent FLT3 Inhibitor for Acute Myeloid Leukemia (AML) Treatment

Kun Du, Yanan He, Jinyang Fu, Guimin Xue, Zhiqiang Zhang iD, Xiaokun Li iD, Yanle Zhi iD

Drug Development Research · 2025

DOI: 10.1002/ddr.70119 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Development Research, 2025. Verfasst von Kun Du und 6 weiteren Autor:innen. Beteiligte Einrichtung: Henan University of Chinese Medicine, Zhengzhou, PR China. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Leukemia, Myeloid, Acute, Drug Design, Protein Kinase Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 23 Literaturangaben. Gefördert von: This study was funded by National Natural Science Foundation of China, grant number 82003566 and Henan Excellent Youth Found (Program No. 242300421091) and Pro….

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is a clonal malignant proliferative disease of myeloid progenitor cells in the hematopoietic system, with a lower than 5‐year overall survival rate. At present, three FLT3 inhibitors have been approved, but these drugs are prone to cause resistance after a period of medication. Developing new FLT3 inhibitors with novel structures is an effective strategy to enhance drug treatment efficacy. This study presents an extension of our effort to design and synthesize a series of novel pyrimidine‐2,4‐diamine derivatives as inhibitors of FLT3. The most active compound, 7r , showed significant inhibition against FLT3 with IC 50 value of 7.82 nM. In addition, 7r exhibited prominent anticancer activities against AML cell lines, such as MV4‐11 (IC 50 = 46.07 nM) and MOLM‐13 (IC 50 = 51.6 nM). Compound 7r inhibited phosphorylation of FLT3 pathways in a dose‐dependent manner in MV4‐11 cell lines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3Leukemia, Myeloid, AcuteDrug DesignProtein Kinase InhibitorsAntineoplastic AgentsPyrimidinesHumansCell Line, TumorCell ProliferationStructure-Activity RelationshipDose-Response Relationship, Drug

Stichwörter der Autor:innen

FLT3MV4‐11acute myeloid leukemiakinase inhibitor

Substanzen

fms-Like Tyrosine Kinase 3FLT3 protein, humanProtein Kinase InhibitorsAntineoplastic AgentsPyrimidines

Autor:innen und Institutionen

  • Henan University of Chinese Medicine, Zhengzhou, PR China.

ORCID-Profile: Zhiqiang Zhang, Xiaokun Li, Yanle Zhi

Förderung

  • This study was funded by National Natural Science Foundation of China, grant number 82003566 and Henan Excellent Youth Found (Program No. 242300421091) and Pro…

Zitieren

APA

Du, K., He, Y., Fu, J., Xue, G., Zhang, Z., Li, X., & Zhi, Y. (2025). Design, Synthesis, and Biological Evaluation of Potent FLT3 Inhibitor for Acute Myeloid Leukemia (AML) Treatment. Drug Development Research. https://doi.org/10.1002/ddr.70119

Vancouver

Du K, He Y, Fu J, Xue G, Zhang Z, Li X, et al. Design, Synthesis, and Biological Evaluation of Potent FLT3 Inhibitor for Acute Myeloid Leukemia (AML) Treatment. Drug Development Research. 2025. doi:10.1002/ddr.70119

BibTeX
@article{Du2025,
  author = {Du, Kun and He, Yanan and Fu, Jinyang and Xue, Guimin and Zhang, Zhiqiang and Li, Xiaokun and Zhi, Yanle},
  title = {Design, Synthesis, and Biological Evaluation of Potent FLT3 Inhibitor for Acute Myeloid Leukemia (AML) Treatment},
  journal = {Drug Development Research},
  year = {2025},
  doi = {10.1002/ddr.70119}
}
Kostenlos starten →